CRISPR Therapeutics AG (CRSP) Total Non-Current Liabilities (2015 - 2026)

CRISPR Therapeutics AG has reported Total Non-Current Liabilities for 12 years, with the latest figure at $905.3 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 171.36% year-over-year to $905.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $905.3 million (up 171.36% YoY) and the FY2025 annual result came in at $337.3 million, up 10.04% from the prior year.
• Total Non-Current Liabilities climbed to $905.3 million in Q1 2026 per CRSP's latest filing, from $337.3 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $905.3 million in Q1 2026 and troughed at $306.5 million in Q4 2024.
• A 5-year average of $380.9 million and a median of $353.6 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities retreated 11.58% in 2025, then jumped 171.36% in 2026.
• Over 5 years, Total Non-Current Liabilities stood at $361.6 million in 2022, then retreated by 4.37% to $345.8 million in 2023, then decreased by 11.36% to $306.5 million in 2024, then increased by 10.04% to $337.3 million in 2025, then jumped by 168.41% to $905.3 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $905.3 million, $337.3 million, and $324.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.